MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
Strengthened financial position resulting from recently announced MARGENZA ® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ ® ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call scheduled for today at?